Consensus Statement
Recently published articles about Consensus Statement
Consensus Statement
Ketamine/Esketamine in Clinical Practice: Areas of Consensus and Non-consensus From an ASCP Task Force
November 2, 2026
The American Society of Clinical Psychopharmacology convened an expert task force to address questions about practical use of these agents in “real world” settings.
Consensus Statement
Next-Step Treatment Options for Treatment-Resistant Depression
January 21, 2026
Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment
May 7, 2025
Consensus recommendations about the goals of a consultation for treatment-resistant depression include establishing the primary diagnosis and comorbidities, clarifying symptoms, identifying goals, documenting treatment history, identifying treatment barriers, and...
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
April 28, 2025
Key practical considerations are described, including systems-level and financial issues; equity and access to TRD care for a diverse population; selecting a target population and facilitating referrals; communication between...
Consensus Statement
Synopsis of the VA/DOD Clinical Practice Guideline for Management of Bipolar Disorder
January 13, 2025
This synopsis focuses on clinically relevant recommendations related to identification and management of bipolar disorder, including the acute and maintenance phases of illness.
Recent JCP Articles on Consensus Statement
Recent PCC Articles on Consensus Statement
Rounds in the General Hospital
Medical Traumatic Stress and Medical Posttraumatic Stress Disorder Following Illness and Treatment: What Primary Care Providers Need to Know
November 12, 2026
Medical PTSD has been associated with debilitating mental health symptoms and a decreased quality of life, as well as with worse medical outcomes.
Expert Commentary
DT120 for Generalized Anxiety Disorder: Findings From Phase 2b and Phase III Trials
November 11, 2026
Lori Davis, MD, reviews clinical trial findings on DT120, an oral disintegrating tablet formulation of lysergide, for generalized anxiety disorder. She describes efficacy findings across a phase 2b trial...
Featured Consensus Statement Research
Expert Commentary
Challenges in Psychedelic Research Trials for Anxiety and Mood Disorders
November 11, 2026
Lori Davis, MD, of the University of Alabama at Birmingham describes methodological and clinical challenges in psychedelic research trials for anxiety and mood disorders. She discusses functional unblinding, expectancy...
Consensus Statement
Screening, Diagnosis, and Treatment of Tardive Dyskinesia
January 28, 2020
Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
